A study of new treatment by JAK-STAT inhibition for central nervous system lymphoma

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10332
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Kobe University
• Principal Investigator: Nishihara Masamitsu 神戸大学, 医学研究科, 医学研究員 (20452493)
• Co-Investigator(Kenkyū-buntansha): 篠山 隆司 神戸大学, 医学部附属病院, 講師 (10379399) ; 田中 一寛 神戸大学, 医学研究科, 特定助教 (70467661) ; 水川 克 神戸大学, 医学部附属病院, 非常勤講師 (80403260)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: lymphoma / JAK / STAT / IL-10

Outline of Final Research Achievements

Cerebrospinal fluid (CSF) interleukin-10 (IL-10) level was associated with activation level of JAK-STAT pathway in central nervous system lymphoma (PCNSL). PCNSL with high CSF IL-10 had strong expression of PIN-1 and SOCS, downstream molecules of JAK-STAT pathway. In addition, CSF IL-10 levels were associated with infiltration levels of tumor associated macrophages (TAMs) in PCNSL. When IL-10 protein was injected into inoculated subcutaneous PCNSL tumor of mouse, JAK and STAT3 in tumor cells was phosphorylated and activated by IL-10. But, JAK/STAT inhibitors could not show a antitumor effect in mouse models.

Free Research Field

脳腫瘍